CEO · Johnson & Johnson
Joaquin Duato
Chairman & CEO, Johnson & Johnson
Joaquin Duato became CEO of Johnson & Johnson in January 2022 and later also became its chairman. Born in Spain, he joined the company in 1989 and held leadership roles in its pharmaceutical business. Johnson & Johnson focuses on medicines and medical technology. The documents are the CEO's own words to shareholders, such as yearly letters or the prepared remarks that open quarterly earnings calls. MouthMath counts 4 documents from 2025 to 2026. Leaving out common words, the most used are “growth”, “sales” and “johnson”.
What the numbers show
MouthMath counts 5,385 words across 4 documents from 2025 to 2026, using 1,111 different words. Leaving out common words, “growth” leads with 58 uses (10.8 per 1,000 words), ahead of “sales” (49) and “johnson” (38). The rest of the top eight: “year”, “billion”, “operational”, “patients”, “strong”. In the newest document, from July 15, 2026, the top word is “quarter” (11), and “q2” rose the most compared with earlier documents (7.5 vs. 0.0 per 1,000 words). Compared with the other 27 CEOs on MouthMath, “sales” stands out: 9.1 uses per 1,000 words here vs. 0.6 for the rest of the group. The opposite is “ai”, one of the group's most used words, at 0.2 per 1,000 words here vs. 5.9 for the others. Counts leave out words like “the” and “and”, and they change as new documents are added.
Top 25 words
The most used words across all 4 documents (5,385 words in all), leaving out common words such as “the”, “and” and “of”.
| Rank | Word | Times said |
|---|---|---|
| 1 | growth | 58 |
| 2 | sales | 49 |
| 3 | johnson | 38 |
| 4 | year | 38 |
| 5 | billion | 29 |
| 6 | operational | 29 |
| 7 | patients | 29 |
| 8 | strong | 28 |
| 9 | first | 27 |
| 10 | quarter | 27 |
| 11 | treatment | 25 |
| 12 | new | 23 |
| 13 | portfolio | 22 |
| 14 | across | 20 |
| 15 | fda | 19 |
| 16 | multiple | 18 |
| 17 | momentum | 17 |
| 18 | approval | 16 |
| 19 | cancer | 16 |
| 20 | delivered | 16 |
| 21 | innovation | 16 |
| 22 | tremfya | 16 |
| 23 | growing | 15 |
| 24 | immunology | 15 |
| 25 | line | 15 |
Documents counted
Each link opens the original on investor.jnj.com.
- Q2 2026 Earnings Call: CEO Prepared Remarks · July 15, 2026 · 1,193 words
- Q1 2026 Earnings Call: CEO Prepared Remarks · April 14, 2026 · 1,073 words
- Q4 2025 Earnings Call: CEO Prepared Remarks · January 21, 2026 · 1,420 words
- Q3 2025 Earnings Call: CEO Prepared Remarks · October 14, 2025 · 1,699 words